This statistic displays the top 10 global pharmaceutical companies based on their vaccine revenue market share worldwide in 2017, and a projection for 2024. Pfizer is expected to account for some 16 percent of the global vaccine market by 2024, largely due to success with its pneumococcal vaccine, Prevnar 13. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.

Top 10 Pharmaceutical Companies Based on Global Vaccine Revenue Market Share in 2017 and 2024

Global Vaccine Revenue Market Size from 2014-2020 (Billion Dollars)


The data from the IFF reference statistic database indicates that the global vaccine market is a huge market opportunity. Almost every participant can get enough profit from the vaccine industry.

IFF pointed out that some vaccines have a major impact on people's health. Eg: Flu Vaccination

Catching the flu might be a hassle for some, but it can be a life-threatening condition for others. Small children, people with pre-existing conditions and the elderly are at an increased risk of dying from a serious flu infection. Up to 650 000 people succumb to the disease every year around the globe. In industrialized countries, most of these deaths occur in the age range of 65 and older. Knowing this, it is surprising how few elderly people are regularly vaccinated against the disease even in more prosperous nations.

In fact, immunization rates vary widely across the globe. While countries like Korea and Mexico top the list with immunization rates above 80 percent for those 65 an older, even industrialized nations like Spain, Japan or France only manage to vaccinate around half of their elderly population. According to data from the OECD, Germany, Norway and Denmark fare even worse, only vaccinating between 30-40 percent of seniors.

Nations that vaccinate a lot of older people often do so as a result of government immunization programs directly targeting the elderly. In Brazil, for example, immunization campaigns have been taking place since 1999, where flu shots are given out for free.

In developing nations, it’s mainly children who are at risk of dying from influenza, according to research by the World Health Organization. Immunization rates for poorer nations are often significantly lower or not even known. But a high immunization rate does not always translate into a significant decrease in flu deaths – researchers must also predict outbreak times and flu strains accurately and hospitals must be able to administer the right care to effectively help a flu patient.